Stocks · News reference
Top analysts changed outlook on top names. For all changes, see analyst ratings page. See how analysts view HOOD, FXNC, NU, FTH, FRST.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Read original at benzingaNeedham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
Read original at benzinga— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR
Read original at benzingaHC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
Read original at benzingaFiled: 2026-08-13 AccNo: 0001437749-26-027512 Size: 160 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarSoFi Technologies relaunched its premium SoFi Plus membership in Q2 2026, reaching 206,000 paid subscribers with $24 million in annualized revenue. The subscription strategy is working, with 25% of subscribers adding additional products. Management aims for 1 million subscribers within a year, implying $120 million in annual revenue. Meanwhile, competitors Robinhood and Chime are expanding their financial services offerings.
Read original at zacks-investment-research